EPA Adds Abortion Drugs to Water Screening
Water utilities should note that this pharmaceutical screening runs separately from their Safe Drinking Water Act contaminant testing.
Updated on Nov. 4, 2026 in Utilities

Live Poll
Should the government test drinking water for pharmaceutical residues like medications?
The Environmental Protection Agency announced on September 9, 2026 that it will test U.S. water supplies for mifepristone and misoprostol, two drugs used in medication abortion, as part of a screening covering more than 1,400 pharmaceuticals, pesticides, and other chemicals. For utilities and water systems, the screening is separate from the agency's testing of unregulated contaminants under the Safe Drinking Water Act.
Why it matters
The EPA says the testing aims to improve understanding of which pollutants may be present in drinking water. The move follows more than a year of lobbying by Students for Life of America, which asked the agency to investigate the drugs, and anti-abortion activists have called the testing a victory for common sense.
The EPA's screening covers more than 1,400 pharmaceuticals, pesticides, and other chemicals in U.S. water supplies, with mifepristone, misoprostol, testosterone, progesterone, and levonorgestrel among the named substances. No baseline detection figures were reported, and the testing is distinct from the agency's unregulated contaminant monitoring under the Safe Drinking Water Act.
The players
U.S. Environmental Protection Agency
The federal agency that sets and enforces drinking water standards and oversees water utilities through the Safe Drinking Water Act.
Students for Life of America
An anti-abortion advocacy organization that lobbied the EPA for more than a year to investigate the drugs in water supplies.
The details
Under the program, the EPA will screen water supplies for the listed substances. Because the effort is separate from the unregulated contaminant testing required under the Safe Drinking Water Act, utilities should not assume it substitutes for their existing monitoring obligations. Levonorgestrel, which is used in contraceptives including emergency contraception such as Plan B, is among the substances included in the screening.
Timeline
September 9, 2026: EPA announces it will test water supplies for mifepristone and misoprostol.
Market Landscape
The screening runs parallel to the unregulated contaminant testing the Safe Drinking Water Act already requires, so utilities now face a separate federal review of pharmaceutical residues in their supplies. It shows the EPA widening its water-quality attention to medications that the existing contaminant framework does not cover.
Water utilities should monitor for any EPA guidance on how the screening results will be shared or used, and should review their current testing programs against the Safe Drinking Water Act obligations that remain separate. Operators should also plan for possible public questions about pharmaceuticals in their supplies, since the screening names medications that are widely prescribed.
The takeaway
Water utilities should treat the EPA's September 9, 2026 screening as a separate track from their Safe Drinking Water Act obligations and keep their own monitoring records current. Operators should watch for EPA publication of screening methods and results, since those will show whether the pharmaceutical findings lead to new standards.
Further reading
For more on how federal rules shape water providers, see Utilities coverage on this site.
Source note: This article includes information reported by The BMJ.
Live Poll
Should the government test drinking water for pharmaceutical residues like medications?




